Bush-Francis catatonia rating scale Trials in Disease

Study on Sodium Oxybate for Treating Catatonia in Patients with Depression, Bipolar Disorder, or Psychotic Disorder

This clinical trial, taking place in the Netherlands, is investigating whether sodium oxybate can serve as an effective new treatment for catatonia in patients with certain mental health conditions. Catatonia is a complex neuropsychiatric condition where people may experience difficulty moving, remain in fixed positions for long periods, become unresponsive, or show unusual motor behaviors. This study specifically focuses on patients whose catatonia occurs alongside depression, bipolar disorder, or psychotic disorders.

Who can participate:

• Adults aged 18 years or older
• Patients currently admitted to an acute psychiatric ward for catatonia treatment
• People whose catatonia has not improved with usual care, which typically involves increasing doses of lorazepam up to 24 mg over 4 days
• Individuals diagnosed with unipolar depressive disorder, bipolar disorder, or a psychotic disorder according to DSM-5 criteria
• Those whose catatonia symptoms have been present for no more than eight weeks

Who cannot participate:

• People younger than 18 years or older than 65 years
• Patients who do not have a catatonia diagnosis
• Individuals unable to provide their own consent to participate in the study

What the trial involves:

The study uses the Bush-Francis Catatonia Rating Scale to measure and track catatonia symptoms throughout the trial. Participants receive sodium oxybate, administered as an oral liquid solution, over a four-day treatment period. The medication is being compared to standard care approaches to determine if it can effectively reduce catatonia symptoms.

Sodium oxybate works by affecting certain chemical messengers in the brain, particularly gamma-aminobutyric acid (GABA) receptors. This helps to stabilize mood and potentially reduce catatonia symptoms. While this medication is already used to treat narcolepsy with cataplexy, its use for catatonia is still being investigated.

How effectiveness is measured:

After four days of treatment, researchers evaluate whether the medication has worked by checking if there has been at least a 50% reduction in catatonia symptoms as measured by the rating scale. Participants are closely monitored throughout the treatment period, with possible follow-up assessments to check for any long-term effects.

The goal of this research is to determine whether sodium oxybate can provide a new treatment option for patients who do not respond well to usual catatonia treatments like lorazepam. This could potentially lead to better management options for people experiencing catatonia in the context of depression, bipolar disorder, or psychotic disorders.